Hormonal Medications: Clinical Approaches and Technological Advancements

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Clinical Pharmaceutics".

Deadline for manuscript submissions: 31 August 2025 | Viewed by 277

Special Issue Editors


E-Mail Website
Guest Editor
Postgraduate Program in Pharmaceutical Sciences, Department of Pharmacy, Center for Studies in Bio-Pharmacy, Federal University of Paraná, Curitiba 80210-170, Brazil
Interests: pharmacokinetics; drug monitoring; health technology assessment; artificial intelligence; clinical pharmacology; phytotherapy; natural products
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Division of Pharmacy and Optometry, The University of Manchester, Manchester, UK
Interests: machine learning; drug monitoring; health technology assessment; drug safety; clinical pharmacology

E-Mail Website
Guest Editor Assistant
Postgraduate Program in Pharmaceutical Sciences, Department of Pharmacy, Center for Studies in Bio-Pharmacy, Federal University of Paraná, Curitiba 80210-170, Brazil
Interests: drug delivery systems; pharmacokinetics; drug monitoring; health technology assessment; drug safety; natural products
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue aims to explore the latest clinical and technological advancements in the monitoring and management of hormonal medications. Hormonal therapies play a pivotal role in the treatment of various medical conditions such as cancer, diabetes, infertility, and hormonal imbalances. However, the effectiveness, safety, and precision of these therapies require careful monitoring to optimize outcomes. We invite researchers to submit original research articles, reviews, and case studies that address a wide range of topics, including but not limited to:

  • Hormonal therapies in cancer treatment
  • Hormonal management in diabetes and infertility
  • The abuse and misuse of hormones in clinical practice
  • Development and optimization of drug delivery systems for hormonal medications
  • Controlled-release devices for hormone therapies
  • Pharmacokinetics and pharmacodynamics of hormonal medications
  • Preclinical and clinical studies evaluating the safety and efficacy of hormonal treatments
  • Systematic reviews assessing the outcomes of hormonal therapies
  • Studies integrating artificial intelligence in monitoring and optimizing hormonal therapies

Contributions focusing on the integration of advanced technologies, monitoring systems, and data analytics in hormonal medication management are highly encouraged. The Special Issue will provide a comprehensive overview of current trends and emerging innovations in the field, ultimately contributing to improved therapeutic strategies and patient care.

Prof. Dr. Roberto Pontarolo
Dr. Alexandre Cobre
Guest Editors

Dr. Raul Edison Luna Lazo
Guest Editor Assistant

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hormonal medications
  • drug monitoring
  • cancer
  • diabetes
  • drug delivery
  • hormone therapies
  • clinical studies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

20 pages, 4021 KiB  
Systematic Review
Safety Profile of Gestrinone: A Systematic Review
by Vitor Luis Fagundes, Nathália Carolina Barreiro Marques, Amanda Franco de Lima, Alexandre de Fátima Cobre, Fernanda Stumpf Tonin, Raul Edison Luna Lazo and Roberto Pontarolo
Pharmaceutics 2025, 17(5), 638; https://doi.org/10.3390/pharmaceutics17050638 - 11 May 2025
Viewed by 147
Abstract
Background: Gestrinone is a synthetic hormone derived from 19-nortestosterone, exhibiting androgenic, anabolic, anti-progestogenic, and antiestrogenic effects. Gestrinone subcutaneous implants have been used “off label” for aesthetic purposes due to their anabolic action, promoting accelerated metabolism and muscle gain. Objective: Our goal is to [...] Read more.
Background: Gestrinone is a synthetic hormone derived from 19-nortestosterone, exhibiting androgenic, anabolic, anti-progestogenic, and antiestrogenic effects. Gestrinone subcutaneous implants have been used “off label” for aesthetic purposes due to their anabolic action, promoting accelerated metabolism and muscle gain. Objective: Our goal is to conduct a systematic review focused exclusively on identifying the safety profile of gestrinone use, without addressing efficacy. Methods: This systematic review was performed according to the Joanna Briggs Institute and Cochrane Collaboration recommendations and is reported following the Preferred Reporting Items for Systematic Reviews and Network Meta-Analyses. This article’s searches were carried out in the PubMed, Embase, and Web of Science databases. Results: A total of 32 articles were included in this study. The reported adverse events associated with the use of gestrinone were amenorrhea (41.4% of cases), acne, seborrhea (42.7% of reports), decreased libido (26.5%), and hot flushes (24.2%). Other nonspecific symptoms such as hoarseness and cramps were also fairly reported (3.5% and 18.6%, respectively). Other reported effects were associated with breast size reduction (23.7% of patients) and increased transaminases (15.1%). Most studies (40%, n = 24 studies) found significant weight gain (ranging from 0.9 to 8 kg per patient). Abnormalities in bone mineral density were reported in four studies. Conclusions: The evidence remains insufficient to fully understand the risks of gestrinone uses associated with its widespread, unregulated use. Thus, further standardized studies and regulatory oversight to ensure patient safety are needed to mitigate potential health risks. Full article
Show Figures

Figure 1

Back to TopTop